Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial-Reference-Cited by-同舟云学术

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial

Published:2018-04-19 Issue:6 Volume:20 Page:1520-1525
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Frías Juan P.¹^ORCID,Hardy Elise²,Ahmed Azazuddin³,Öhman Peter²,Jabbour Serge⁴^ORCID,Wang Hui²,Guja Cristian⁵^ORCID

Affiliation:

1. National Research Institute; Los Angeles California

2. AstraZeneca; Gaithersburg Maryland

3. Apex Medical Research; Chicago Illinois

4. Division of Endocrinology, Diabetes and Metabolic Diseases; Sidney Kimmel Medical College of Thomas Jefferson University; Philadelphia Pennsylvania

5. Department of Diabetes, Nutrition and Metabolic Diseases; Carol Davila University of Medicine and Pharmacy; Bucharest Romania

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13296/fullpdf

Reference20 articles.

1. Standards of medical care in diabetes-2017;American Diabetes Association;Diabetes Care,2017

2. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetes Care,2012